Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.10.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 60 Months Ended
Sep. 12, 2018
Dec. 22, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Patent and licensing costs     $ 133,985 $ 161,119 $ 594,798 $ 648,867  
Deferred setup and organization costs, amortization period         180 months    
Unrecognized tax benefits        
Tax Reform Law [Member]              
Federal corporate tax rate   21.00%          
Theradex Systems, Inc [Member]              
Total estimated clinical costs to be charged to operations             $ 2,233,248
Percentage of clinical trial service             60.00%
Percentage of clinical center laboratory cost             40.00%
Clinical costs charged to operations         $ 40,225 $ 104,840  
Percentage of research and development costs         20.00% 29.00%  
Theradex Systems, Inc [Member]              
Research and development, description         Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services rendered and payments for pass-through costs of approximately 6%.    
Costs under work $ 954,000